Create Free Account

By creating account you will get access to hot stocks & personalised emails

Imugene Ltd

Healthcare AU IMU

0.056AUD
0.001(1.82%)

Last update at 2024-07-26T02:59:00Z

Day Range

0.060.06
LowHigh

52 Week Range

0.040.15
LowHigh

Fundamentals

  • Previous Close 0.06
  • Market Cap419.05M
  • Volume2909934
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-89.65514M
  • Revenue TTM15.03M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM 11.78M
  • Diluted EPS TTM-0.01

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -39.17108M -37.86917M -18.45536M -10.50800M -7.77536M
Minority interest - - - - -
Net income -39.17108M -37.97592M -25.76667M -14.58706M -7.77568M
Selling general administrative 17.77M 12.10M 9.44M 4.29M 3.81M
Selling and marketing expenses 0.51M 0.33M 0.15M 0.28M 0.43M
Gross profit - - - - 4.13M
Reconciled depreciation 0.19M 0.20M 0.10M 0.08M 0.06M
Ebit -51.29082M -37.65758M -18.34433M -10.50297M -7.76893M
Ebitda -51.10050M -37.45422M -18.24013M -10.42047M -7.70567M
Depreciation and amortization 0.19M 0.20M 0.10M 0.08M 0.06M
Non operating income net other - - - - -
Operating income -51.29082M -37.65758M -18.34433M -10.50297M -7.76893M
Other operating expenses 51.29M 50.67M 25.67M 14.88M 12.39M
Interest expense - 0.11M 0.11M 0.00503M 0.00611M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 1.88M 0.19M 0.13M 0.30M 0.41M
Net interest income 1.85M 0.07M 0.01M 0.30M 0.41M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.84994M 0.11M 7.31M 4.08M 0.00032M
Total revenue - 0.00000M 0.00000M 4.21M 4.54M
Total operating expenses 51.29M 50.67M 25.67M 14.88M 12.39M
Cost of revenue - - - - -
Total other income expense net 10.27M -0.21159M -0.11103M -0.00503M -0.00643M
Discontinued operations - - - - -
Net income from continuing ops -39.17108M -37.86917M -18.45536M -10.50800M -7.77536M
Net income applicable to common shares -37.91489M -37.86917M -18.45536M -10.50800M -7.77536M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 195.81M 147.61M 71.81M 65.20M 30.78M
Intangible assets 30.49M 32.69M 34.89M 30.46M 7.06M
Earning assets - - - - -
Other current assets 0.40M 1.11M 0.17M 0.19M 0.16M
Total liab 7.44M 8.90M 6.79M 5.40M 3.48M
Total stockholder equity 188.37M 138.70M 65.02M 59.81M 27.29M
Deferred long term liab - - - - -
Other current liab 1.92M 1.42M 2.85M 1.43M 0.89M
Common stock 314.40M 230.79M 113.11M 92.80M 63.12M
Capital stock 314.40M 230.79M 113.11M 104.89M 63.12M
Retained earnings -142.69219M -103.52112M -65.65194M -47.31026M -36.81672M
Other liab 0.99M 0.99M 2.17M 2.49M 1.00M
Good will - - - - -
Other assets 0.02M 0.03M 0.02M 0.02M 0.02M
Cash 153.15M 99.89M 29.49M 30.11M 19.05M
Cash and equivalents 49.54M 29.00M 21.00M 25.00M 17.20M
Total current liabilities 6.08M 7.42M 4.46M 2.90M 2.42M
Current deferred revenue 1.63M 1.30M 0.74M 0.39M -
Net debt -152.59719M -99.21429M -29.21600M -30.03742M -18.92502M
Short term debt 0.19M 0.18M 0.11M 0.06M 0.06M
Short long term debt - - - - -
Short long term debt total 0.55M 0.67M 0.27M 0.07M 0.12M
Other stockholder equity -172.96587M -127.26763M -47.45497M -45.48730M 0.99M
Property plant equipment 0.68M 0.86M 0.47M 0.16M 0.23M
Total current assets 164.40M 113.77M 36.32M 34.49M 23.42M
Long term investments 0.22M 0.25M 0.12M 0.08M 0.05M
Net tangible assets 159.14M 106.02M 30.12M 29.35M 20.24M
Short term investments - -0.00000M - - -
Net receivables 10.85M 12.77M 6.66M 4.19M 4.22M
Long term debt - - - - 0.99M
Inventory - - - - -
Accounts payable 2.34M 4.51M 0.76M 1.01M 1.48M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 16.66M 11.44M 17.56M 14.32M 0.99M
Additional paid in capital - - - - -
Common stock total equity - - - 104.89M 63.12M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.02M 0.03M 0.02M 0.02M 0.02M
Deferred long term asset charges - - - - -
Non current assets total 31.41M 33.84M 35.49M 30.71M 7.36M
Capital lease obligations 0.55M 0.67M 0.27M 0.07M 0.12M
Long term debt total 0.36M 0.49M 0.17M 0.00840M 1.05M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments 1.89M -0.13717M -0.03456M -0.03064M -0.02969M
Change to liabilities -1.38542M 2.85M 0.03M -0.99994M 1.89M
Total cashflows from investing activities 1.89M -0.22099M -5.32640M -1.20665M 0.25M
Net borrowings -0.14741M -0.01081M 0.07M -0.05356M -0.04114M
Total cash from financing activities 82.98M 101.34M 17.99M 22.71M 18.77M
Change to operating activities 0.71M -0.94002M 0.02M 0.01M -0.06428M
Net income -37.91489M -37.86917M -18.45536M -10.50800M -7.77568M
Change in cash 53.26M 70.40M -0.61973M 11.06M 11.23M
Begin period cash flow 99.89M 29.49M 30.11M 19.05M 7.82M
End period cash flow 153.15M 99.89M 29.49M 30.11M 19.05M
Total cash from operating activities -31.47096M -30.84814M -13.28001M -10.43777M -7.90949M
Issuance of capital stock 88.17M 108.88M 18.05M 24.57M 20.26M
Depreciation 2.39M 2.41M 1.96M 0.08M 0.06M
Other cashflows from investing activities 1.89M 0.17M 0.16M 0.31M 0.41M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 1.09M -6.10750M -2.45527M -0.03357M -2.30664M
Sale purchase of stock -5.04192M -6.15137M -0.12557M -1.80108M -1.44396M
Other cashflows from financing activities -0.14741M -1.38504M 0.06M -0.05859M -0.04725M
Change to netincome 3.64M 8.81M 5.62M 1.01M 0.28M
Capital expenditures 0.00000M 0.28M 5.45M 1.49M 0.14M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.09M -6.10750M -2.45527M -0.03357M 1.87M
Stock based compensation 5.64M 4.10M 5.56M 1.27M -
Other non cash items 4.05M 4.61M 3.21M -0.01226M 7.71M
Free cash flow -31.47096M -31.12513M -18.72776M -11.92446M -8.05347M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IMU
Imugene Ltd		 0.001 1.82% 0.06 - - 45.25 3.49 - -5.4363
CSL
CSL Ltd		 3.35 1.09% 308.88 41.15 31.35 9.60 5.16 10.91 34.93
TLX
Telix Pharmaceuticals Ltd		 0.10 0.49% 19.32 983.00 21.01 8.47 28.69 8.21 177.65
NEU
Neuren Pharmaceuticals Ltd		 0.35 1.74% 20.45 16.75 38.46 11.63 13.15 10.65 12.39
CU6
Clarity Pharmaceuticals Ltd		 0.04 0.63% 6.34 - - 85.90 15.59 - -18.7407

Reports Covered

Stock Research & News

View All

Profile

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 for gastric cancer; VAXINIA is in phase 1 MAST trial for patients with metastatic or advanced solid tumours; and CHECKvacc oncolytic virotherapy is in phase 1 clinical trial against metastatic triple negative breast cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform; and a license agreement with Precision Biosciences Inc. to acquire azer-cell allogeneic CD19 CAR Tcell therapy program. Imugene Limited is based in Sydney, Australia.

Imugene Ltd

4-6 Bligh Street, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Exec. Chairman 1956
Ms. Leslie Chong CEO, MD & Exec. Director NA
Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D. Chief Technology Officer NA
Dr. Monil Shah M.B.A., Pharm.D. Chief Bus. Officer NA
Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD Chief Financial Officer 1966
Ms. Ursula McCurry Sr. VP of Clinical Operations NA
Dr. Giovanni Selvaggi Chief Medical Officer NA
Mr. Nathan Jong C.A. Joint Company Sec. NA
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Executive Chairman 1956
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Executive Chairman 1956

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.